BABAK GHADISHAH: Open Payments
NPI 1346272408 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,117 in 41 payments from 15 companies in 2025. Trend: 2023 $1,217 · 2024 $1,310 · 2025 $1,117
Food & beverage: $1,117
| Company | Payments | Amount |
|---|---|---|
| Edwards Lifesciences Corporation | 2 | $203 |
| Otsuka America Pharmaceutical, Inc. | 4 | $194 |
| GlaxoSmithKline, LLC. | 5 | $116 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $99 |
| Novo Nordisk Inc | 5 | $90 |
| ABBVIE INC. | 4 | $82 |
| Astellas Pharma US Inc | 4 | $81 |
| PFIZER INC. | 3 | $72 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $39 |
| Medtronic, Inc. | 1 | $33 |
Products named: REXULTI, SAPIEN 3 Ultra RESILIA, JARDIANCE, UBRELVY, Veozah, SHINGRIX, NURTEC ODT, Rybelsus.
Industry payments across NV — which companies pay providers there.
